(0.33%) 5 116.99 points
(0.33%) 38 365 points
(0.37%) 15 987 points
(-0.99%) $83.02
(5.56%) $2.03
(0.34%) $2 355.20
(0.46%) $27.66
(4.05%) $959.45
(-0.26%) $0.932
(-0.41%) $10.98
(-0.57%) $0.796
(1.69%) $93.43
Live Chart Being Loaded With Signals
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders...
Stats | |
---|---|
本日の出来高 | 401 467 |
平均出来高 | 29 535.00 |
時価総額 | 3.02M |
EPS | $0 ( 2024-03-14 ) |
次の収益日 | ( $-0.230 ) 2024-05-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0300 |
ATR14 | $0.122 (0.74%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-25 | Alloway Paul | Buy | 23 530 | Common Stock |
2024-03-25 | Alloway Paul | Sell | 18 090 | Restricted Stock Units |
2024-03-25 | Michaud Charles Jr | Buy | 6 448 | Common Stock |
2024-03-25 | Michaud Charles Jr | Sell | 5 360 | Restricted Stock Units |
2024-01-01 | Tzianabos Arthur | Buy | 19 140 | Common Stock |
INSIDER POWER |
---|
35.88 |
Last 94 transactions |
Buy: 1 681 707 | Sell: 632 243 |
Homology Medicines Inc 相関
10 最も負の相関 | |
---|---|
ZGNX | -0.915 |
ADMS | -0.913 |
UNCY | -0.886 |
RESN | -0.877 |
TYHT | -0.876 |
ORTX | -0.874 |
BLCT | -0.87 |
PLPC | -0.869 |
CNST | -0.864 |
CNCE | -0.861 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Homology Medicines Inc 相関 - 通貨/商品
Homology Medicines Inc 財務諸表
Annual | 2023 |
収益: | $1.16M |
総利益: | $578 000 (50.00 %) |
EPS: | $-1.950 |
FY | 2023 |
収益: | $1.16M |
総利益: | $578 000 (50.00 %) |
EPS: | $-1.950 |
FY | 2022 |
収益: | $3.21M |
総利益: | $609 000 (18.98 %) |
EPS: | $0.00840 |
FY | 2021 |
収益: | $33.97M |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.901 |
Financial Reports:
No articles found.
Homology Medicines Inc
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing for various genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。